Latest Information Update: 23 Feb 2005
At a glance
- Originator Shionogi
- Mechanism of Action Metalloprotease inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Feb 2005 Discontinued - Phase-I/II for Cancer in USA (PO)
- 23 Feb 2005 Discontinued - Phase-I for Cancer in Europe (PO)
- 03 Sep 2003 This compound is still in active development